FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134765316> ?p ?o ?g. }

• W3134765316 endingPage "338" @default.
• W3134765316 startingPage "327" @default.
• W3134765316 abstract "BACKGROUND: The 2015 American Society of Clinical Oncology guidelines recommend first-line treatment of hormone receptor (HR)-positive breast cancer with endocrine therapy plus or minus palbociclib, a selective cyclin-dependent kinase (CDK)4/6 inhibitor. In 2018, the U.S. Food and Drug Administration approved ribociclib, a new orally available selective CDK4/6 inhibitor. While gains in progression-free survival (PFS) and overall survival (OS) from ribociclib are important for clinical and treatment outcomes, trade-offs in adverse events (AEs) and additional costs necessitate cost-effectiveness analysis (CEA) to assist consideration by third-party payer systems, physicians, and patients. OBJECTIVES: To (a) develop a Markov model and (b) determine the cost-effectiveness of ribociclib plus endocrine therapy versus endocrine therapy alone as treatment for premenopausal and perimenopausal patients with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. METHODS: A lifetime 3-state Markov model (stable, progressed, and dead health states) was developed using a U.S. payer perspective. Transition probabilities were calculated based on OS and PFS outcomes from the randomized controlled phase 3 trial MONALEESA-7. These Kaplan-Meier curves were extended to lifetime by estimating best-fit distributions using loglogistic distribution for ribociclib curves and Weibull distribution for placebo curves. Costs were obtained from national data sources using 2019 U.S. dollars (USD) and discounted by 3%. Utilities were obtained via published breast cancer literature and were included for each health state and for time spent with each AE. Results were expressed as an incremental cost-effectiveness ratio (ICER) expressed as USD per quality-adjusted life-year (QALY) saved. Treatments were assumed to be cost-effective based on a willingness-to-pay (WTP) threshold of $150,000 per QALY gained. Base-case, 1-way sensitivity tornado diagrams and probabilistic sensitivity analyses demonstrated changes in the ICER and were driven by the cost of ribociclib and the utility of remaining in the stable health state. RESULTS: Ribociclib plus endocrine therapy was cost-effective at an ICER of $124,513 per QALY when compared with endocrine therapy alone at a WTP threshold of $150,000. The ribociclib plus endocrine therapy arm had an effectiveness of 5.28 QALYs and a total cost of $385,112, while placebo plus endocrine therapy provided only 2.46 QALYs at a lower total cost of $67.246. The model was sensitive to the cost of ribociclib and the utility of time spent in the stable health state. Probabilistic sensitivity analysis demonstrated that endocrine therapy alone was cost-effective until a WTP of $125,000 and was cost-effective 72% of the time at the WTP threshold. CONCLUSIONS: Ribociclib plus endocrine therapy is more cost-effective than endocrine therapy alone. Professionals in managed care settings should consider the pharmacoeconomic benefits of ribociclib for the treatment of HR-positive, HER2-negative breast cancer as they make value-based formulary decisions. Further CEAs should be considered as direct treatment comparison trials between CDK4/6 inhibitors are completed in the future. DISCLOSURES: No outside funding supported this study. The authors have nothing to disclose." @default.
• W3134765316 created "2021-03-15" @default.
• W3134765316 creator A5001503226 @default.
• W3134765316 creator A5018165770 @default.
• W3134765316 creator A5028928110 @default.
• W3134765316 creator A5037438939 @default.
• W3134765316 creator A5047194922 @default.
• W3134765316 creator A5054636078 @default.
• W3134765316 creator A5089204517 @default.
• W3134765316 date "2021-03-01" @default.
• W3134765316 modified "2023-10-12" @default.
• W3134765316 title "Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer" @default.
• W3134765316 cites W1861968676 @default.
• W3134765316 cites W1991054314 @default.
• W3134765316 cites W1992382952 @default.
• W3134765316 cites W2005295931 @default.
• W3134765316 cites W2020677481 @default.
• W3134765316 cites W2023067662 @default.
• W3134765316 cites W2037809152 @default.
• W3134765316 cites W2048687800 @default.
• W3134765316 cites W2056238632 @default.
• W3134765316 cites W2058056848 @default.
• W3134765316 cites W2084572083 @default.
• W3134765316 cites W2116144791 @default.
• W3134765316 cites W2123091553 @default.
• W3134765316 cites W2128611498 @default.
• W3134765316 cites W2143025931 @default.
• W3134765316 cites W2169906750 @default.
• W3134765316 cites W2232585277 @default.
• W3134765316 cites W2345893136 @default.
• W3134765316 cites W2404884142 @default.
• W3134765316 cites W2528767298 @default.
• W3134765316 cites W2560635244 @default.
• W3134765316 cites W2598063839 @default.
• W3134765316 cites W2606892115 @default.
• W3134765316 cites W2621337730 @default.
• W3134765316 cites W2719623628 @default.
• W3134765316 cites W2802776309 @default.
• W3134765316 cites W2804105316 @default.
• W3134765316 cites W2805575723 @default.
• W3134765316 cites W2809230902 @default.
• W3134765316 cites W2903411408 @default.
• W3134765316 cites W2909018550 @default.
• W3134765316 cites W2917999849 @default.
• W3134765316 cites W2948069739 @default.
• W3134765316 cites W2965775308 @default.
• W3134765316 cites W2976415870 @default.
• W3134765316 cites W3037336786 @default.
• W3134765316 cites W3037927110 @default.
• W3134765316 cites W3045121257 @default.
• W3134765316 cites W4229962019 @default.
• W3134765316 cites W4239051461 @default.
• W3134765316 doi "https://doi.org/10.18553/jmcp.2021.27.3.327" @default.
• W3134765316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33645243" @default.
• W3134765316 hasPublicationYear "2021" @default.
• W3134765316 type Work @default.
• W3134765316 sameAs 3134765316 @default.
• W3134765316 citedByCount "5" @default.
• W3134765316 countsByYear W31347653162021 @default.
• W3134765316 countsByYear W31347653162022 @default.
• W3134765316 countsByYear W31347653162023 @default.
• W3134765316 crossrefType "journal-article" @default.
• W3134765316 hasAuthorship W3134765316A5001503226 @default.
• W3134765316 hasAuthorship W3134765316A5018165770 @default.
• W3134765316 hasAuthorship W3134765316A5028928110 @default.
• W3134765316 hasAuthorship W3134765316A5037438939 @default.
• W3134765316 hasAuthorship W3134765316A5047194922 @default.
• W3134765316 hasAuthorship W3134765316A5054636078 @default.
• W3134765316 hasAuthorship W3134765316A5089204517 @default.
• W3134765316 hasBestOaLocation W31347653161 @default.
• W3134765316 hasConcept C112930515 @default.
• W3134765316 hasConcept C121608353 @default.
• W3134765316 hasConcept C126322002 @default.
• W3134765316 hasConcept C142724271 @default.
• W3134765316 hasConcept C143998085 @default.
• W3134765316 hasConcept C197934379 @default.
• W3134765316 hasConcept C204787440 @default.
• W3134765316 hasConcept C27081682 @default.
• W3134765316 hasConcept C2775930923 @default.
• W3134765316 hasConcept C2777329042 @default.
• W3134765316 hasConcept C2779744173 @default.
• W3134765316 hasConcept C2779786085 @default.
• W3134765316 hasConcept C3019080777 @default.
• W3134765316 hasConcept C530470458 @default.
• W3134765316 hasConcept C535046627 @default.
• W3134765316 hasConcept C71924100 @default.
• W3134765316 hasConceptScore W3134765316C112930515 @default.
• W3134765316 hasConceptScore W3134765316C121608353 @default.
• W3134765316 hasConceptScore W3134765316C126322002 @default.
• W3134765316 hasConceptScore W3134765316C142724271 @default.
• W3134765316 hasConceptScore W3134765316C143998085 @default.
• W3134765316 hasConceptScore W3134765316C197934379 @default.
• W3134765316 hasConceptScore W3134765316C204787440 @default.
• W3134765316 hasConceptScore W3134765316C27081682 @default.
• W3134765316 hasConceptScore W3134765316C2775930923 @default.
• W3134765316 hasConceptScore W3134765316C2777329042 @default.
• W3134765316 hasConceptScore W3134765316C2779744173 @default.
• W3134765316 hasConceptScore W3134765316C2779786085 @default.

• next